Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for children and adults with asthma

Esta versión no es la más reciente

ver la versión actual 19 octubre 2021

Información

DOI:
https://doi.org/10.1002/14651858.CD012929Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 22 enero 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Vías respiratorias

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Michaela Edwards

    Faculty of Health and Medicine, Lancaster University, Lancaster, UK

  • Andrew Gallagher

    Lancaster Medical Practice, Lancaster, UK

  • Parameswaran Nair

    Firestone Institute for Respiratory Health, McMaster University & St Joseph`s Healthcare, Hamilton, Canada

  • Stewart Drew

    Children’s Physiotherapy Service, Lancashire Care NHS Foundation Trust, Preston, UK

  • Aashish Vyas

    Department of Respiratory Medicine, Lancashire Teaching Hospitals Trust, Preston, UK

  • Rashmi Sharma

    Department of Microbiology, BTH NHS Foundation Trust, Blackpool, UK

  • Paul A Marsden

    Faculty of Health and Medicine, Lancaster University, Lancaster, UK

    Department of Respiratory Medicine, Lancashire Teaching Hospitals Trust, Preston, UK

  • David JW Evans

    Correspondencia a: Lancaster Health Hub, Lancaster University, Lancaster, UK

    [email protected]

Contributions of authors

David JW Evans: Developed the protocol.

Michaela Edwards: Developed the protocol.

Andrew Gallagher: Developed the protocol.

Parameswaran Nair: Developed the protocol.

Aashish Vyas: Developed the protocol.

Rashmi Sharma: Developed the protocol.

Paul A Marsden: Developed the protocol.

Sources of support

Internal sources

  • Lancaster University, UK.

    David Evans is employed by Lancaster University as a Senior Research Associate. As part of his role, David works on Cochrane systematic reviews.

External sources

  • The authors declare that no such funding was received for this systematic review, Other.

Declarations of interest

David JW Evans: Provides freelance medical writing services to medical communications agencies.

Michaela Edwards: None.

Andrew Gallagher: None.

Parameswaran Nair: In the past 2 years, has received research grants from Roche, Teva, Sanofi, AZ, Novartis, and BI, and has provided consultation and received honoraria from Roche, Teva, Sanofi, AZ, Novartis, Theravance, Knopp.

Drew Stuart: None.

Aashish Vyas: None.

Rashmi Sharma: None.

Paul A Marsden: Has received lecture fees and conference accommodation and fees from industry unrelated to the current review.

Acknowledgements

Thank you to Elizabeth Stovold for assisting with the search strategy, and to Chris Cates, Emma Jackson, Rebecca Normansell, Emma Dennett, and Steve Milan for providing advice and support. The authors thank Lise Estcourt (consumer representative) for critical review of the protocol.

The Background and Methods section of this protocol are based on a standard template used by Cochrane Airways.

This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2021 Oct 19

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma

Review

Andrew Gallagher, Michaela Edwards, Parameswaran Nair, Stewart Drew, Aashish Vyas, Rashmi Sharma, Paul A Marsden, Ran Wang, David JW Evans

https://doi.org/10.1002/14651858.CD012929.pub2

2018 Jan 22

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for children and adults with asthma

Protocol

Michaela Edwards, Andrew Gallagher, Parameswaran Nair, Stewart Drew, Aashish Vyas, Rashmi Sharma, Paul A Marsden, David JW Evans

https://doi.org/10.1002/14651858.CD012929

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.